• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无传染病专家医院中,医院医师在新冠病毒管理方面的作用。

Hospitalists' COVID-19 management roles in hospitals without infectious disease specialists.

机构信息

Department of General Medicine, Nara City Hospital, Nara, Japan.

Department of Clinical Epidemiology, Hyogo Medical University, Hyogo, Japan.

出版信息

Hosp Pract (1995). 2024 Aug;52(3):91-97. doi: 10.1080/21548331.2024.2337614. Epub 2024 Apr 3.

DOI:10.1080/21548331.2024.2337614
PMID:38566604
Abstract

BACKGROUND

Hospitalists may work in a variety of clinical settings to manage COVID-19 cases. However, the extent of their involvement in COVID-19 care is unknown, particularly in hospitals without infectious disease (ID) specialists.

METHODS

This study aimed to confirm whether hospitalists provided COVID-19 management in various clinical settings when ID specialists were unavailable. We conducted a multicenter cross-sectional study using a web-based questionnaire. The participants were full-time hospitalists working in Japanese academic community-based hospitals. The study period was from 15 January 2021 to 15 February 2021, during Japan's third wave of the COVID-19 pandemic. The primary outcome was the rate of hospitalists participating in COVID-19 inpatient management in hospitals with or without ID specialists.

RESULTS

ID specialists were absent in 31% of small hospitals (those with fewer than 249 registered beds), but only 4% of large hospitals ( < 0.001). Hospitalists were more likely to manage both COVID-19 inpatient care and emergency department care in hospitals without than with hospitals with ID specialists (76 versus 56% ( = 0.01) and 90 versus 73% ( = 0.01), respectively). After adjusting for confounders by multivariate analysis, hospitalists who worked in hospitals without ID specialists had higher odds of participating in COVID-19 inpatient care than those who worked in hospitals with such specialists (adjusted odds ratio: 3.0, 95% CI: 1.2-7.4).

CONCLUSION

Hospitalists were more likely to provide COVID-19 inpatient care in various clinical settings in hospitals without ID specialists.

摘要

背景

医院医师可能在各种临床环境中工作,以管理 COVID-19 病例。然而,他们在 COVID-19 护理中的参与程度尚不清楚,尤其是在没有传染病(ID)专家的医院中。

方法

本研究旨在确认在 ID 专家不可用时,医院医师是否在各种临床环境中提供 COVID-19 管理。我们使用基于网络的问卷进行了一项多中心横断面研究。参与者是在日本学术社区医院工作的全职医院医师。研究期间为 2021 年 1 月 15 日至 2021 年 2 月 15 日,正值日本 COVID-19 疫情的第三波。主要结局是在有或没有 ID 专家的医院中,医院医师参与 COVID-19 住院管理的比例。

结果

在小医院(注册床位少于 249 张)中,ID 专家缺席的比例为 31%,但在大医院( < 0.001)中仅为 4%。与有 ID 专家的医院相比,在没有 ID 专家的医院中,医院医师更有可能管理 COVID-19 住院患者和急诊科患者(分别为 76%比 56%( = 0.01)和 90%比 73%( = 0.01))。通过多变量分析调整混杂因素后,与在有 ID 专家的医院工作的医院医师相比,在没有 ID 专家的医院工作的医院医师更有可能参与 COVID-19 住院患者的治疗(调整后的优势比:3.0,95%CI:1.2-7.4)。

结论

在没有 ID 专家的医院中,医院医师更有可能在各种临床环境中提供 COVID-19 住院患者的治疗。

相似文献

1
Hospitalists' COVID-19 management roles in hospitals without infectious disease specialists.无传染病专家医院中,医院医师在新冠病毒管理方面的作用。
Hosp Pract (1995). 2024 Aug;52(3):91-97. doi: 10.1080/21548331.2024.2337614. Epub 2024 Apr 3.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
3
Sexual Harassment and Prevention Training性骚扰与预防培训
4
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
5
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
6
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
7
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
8
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
9
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
10
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.COVID-19 患者使用激素避孕的血栓栓塞风险。
Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD014908. doi: 10.1002/14651858.CD014908.pub2.

引用本文的文献

1
Use of Internet/Application-Based E-consults by General Practitioners in Japan to Resolve Patients' Problems: A Descriptive Observational Study.日本全科医生使用基于互联网/应用程序的电子咨询来解决患者问题:一项描述性观察研究。
Cureus. 2024 Dec 31;16(12):e76690. doi: 10.7759/cureus.76690. eCollection 2024 Dec.